Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
J Korean Med Sci. 2012 Nov;27(11):1378-84. doi: 10.3346/jkms.2012.27.11.1378. Epub 2012 Oct 30.
Primary CNS lymphoma (PCNSL) is a very uncommon disease in children, and usually treated by chemotherapy, combined with focal or craniospinal radiotherapy (RT). However, adverse effects of RT are a concern. We evaluated the outcomes of childhood PCNSL, treated with systemic and intrathecal chemotherapy, but without RT. For fifteen years, six patients among 175 of non-Hodgkin lymphoma were diagnosed as PCNSL in Seoul National University Children's Hospital and we analyzed their medical records retrospectively. Their male:female ratio was 5:1, and median age was 10.1 yr. The primary sites were the sellar area in three patients, parietal area in one, cerebellum in one, and multiple areas in one. Their pathologic diagnoses were diffuse large B-cell lymphoma in three patients, Burkitt lymphoma in two, and undifferentiated B-cell lymphoma in one. Five were treated with the LMB96 treatment protocol, and one was treated with the CCG-106B protocol. None had RT as a first-line treatment. One patient had a local relapse and received RT and salvage chemotherapy, without success. No patient had treatment-related mortality. Their estimated 5-yr event-free and overall survival rates were both 83.3%. In conclusion, PCNSL is a rare disease in childhood, but successfully treated by chemotherapy without RT.
原发性中枢神经系统淋巴瘤(PCNSL)在儿童中非常罕见,通常采用化疗联合局部或全脑脊髓放疗(RT)治疗。然而,RT 的不良反应令人担忧。我们评估了 175 例非霍奇金淋巴瘤患儿中,6 例接受全身和鞘内化疗而未接受 RT 治疗的 PCNSL 患儿的结局。在首尔国立大学儿童医院,15 年来,175 例非霍奇金淋巴瘤患儿中有 6 例被诊断为 PCNSL,我们对这些患儿的病历进行了回顾性分析。患儿的男女比例为 5:1,中位年龄为 10.1 岁。3 例患儿的原发部位为鞍区,1 例为顶叶,1 例为小脑,1 例为多部位。3 例患儿的病理诊断为弥漫性大 B 细胞淋巴瘤,2 例为伯基特淋巴瘤,1 例为未分化 B 细胞淋巴瘤。5 例患儿接受 LMB96 治疗方案,1 例患儿接受 CCG-106B 方案治疗。所有患儿均未将 RT 作为一线治疗。1 例患儿局部复发,接受 RT 和挽救化疗,但未成功。无患儿因治疗相关死亡。患儿的 5 年无事件生存率和总生存率均为 83.3%。总之,PCNSL 在儿童中较为罕见,但可通过化疗而非 RT 成功治疗。